Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pavan K Bendapudi

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
NEJM Evidence|February 6, 2024
When Is It Preferable to Use Warfarin?Pavan K Bendapudi
Hematology. American Society of Hematology. Education Program|December 9, 2022
Evidence-Based Minireview: Should caplacizumab be used routinely in unselected patients with immune thrombotic thrombocytopenic purpura?George Goshua, Pavan K Bendapudi
Transfusion|December 9, 2023
Fatal hemolytic disease of the newborn due to anti-B Isohemagglutinin: An unfamiliar presentation of a familiar diseaseMckenna Longacre, Pavan K Bendapudi
American Journal of Clinical Pathology|February 12, 2016
An Algorithmic Approach to the Diagnosis and Management of the Thrombotic MicroangiopathiesPavan K Bendapudi, Robert S Makar
British Journal of Haematology|July 14, 2020
Assessing the risk of refractory disease in iTTPRobert S Makar, Pavan K Bendapudi
Transfusion Medicine Reviews|November 22, 2017
Purpura Fulminans: Mechanism and Management of Dysregulated HemostasisMeaghan E Colling, Pavan K Bendapudi
Journal of Thrombosis and Haemostasis : JTH|March 9, 2026
Targeting FXI for VTE prevention: a tale of two antibodiesSteven P Grover, Pavan K Bendapudi
Blood|January 9, 2025
How I diagnose and treat acute infection-associated purpura fulminansPavan K Bendapudi, Julie-Aurore Losman
Journal of Thrombosis and Haemostasis : JTH|August 21, 2025
"Loss of function in protein Z (PROZ) is associated with increased risk of ischemic stroke in the UK Biobank": replyAmelia K Haj, Pavan K Bendapudi
Journal of Thrombosis and Haemostasis : JTH|July 20, 2023
Heat shock protein 47 and venous thrombosis: letting sleeping bears lieSteven P Grover, Nigel Mackman, Pavan K Bendapudi
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
NEJM Evidence|February 6, 2024
When Is It Preferable to Use Warfarin?Pavan K Bendapudi
Hematology. American Society of Hematology. Education Program|December 9, 2022
Evidence-Based Minireview: Should caplacizumab be used routinely in unselected patients with immune thrombotic thrombocytopenic purpura?George Goshua, Pavan K Bendapudi
Transfusion|December 9, 2023
Fatal hemolytic disease of the newborn due to anti-B Isohemagglutinin: An unfamiliar presentation of a familiar diseaseMckenna Longacre, Pavan K Bendapudi
American Journal of Clinical Pathology|February 12, 2016
An Algorithmic Approach to the Diagnosis and Management of the Thrombotic MicroangiopathiesPavan K Bendapudi, Robert S Makar
British Journal of Haematology|July 14, 2020
Assessing the risk of refractory disease in iTTPRobert S Makar, Pavan K Bendapudi
Transfusion Medicine Reviews|November 22, 2017
Purpura Fulminans: Mechanism and Management of Dysregulated HemostasisMeaghan E Colling, Pavan K Bendapudi
Journal of Thrombosis and Haemostasis : JTH|March 9, 2026
Targeting FXI for VTE prevention: a tale of two antibodiesSteven P Grover, Pavan K Bendapudi
Blood|January 9, 2025
How I diagnose and treat acute infection-associated purpura fulminansPavan K Bendapudi, Julie-Aurore Losman
Journal of Thrombosis and Haemostasis : JTH|August 21, 2025
"Loss of function in protein Z (PROZ) is associated with increased risk of ischemic stroke in the UK Biobank": replyAmelia K Haj, Pavan K Bendapudi
Journal of Thrombosis and Haemostasis : JTH|July 20, 2023
Heat shock protein 47 and venous thrombosis: letting sleeping bears lieSteven P Grover, Nigel Mackman, Pavan K Bendapudi
Pageof 6